ONCAlert | Upfront Therapy for mRCC

Gastric Cancer VIEW MORE >>

The combination of pegylated human hyaluronidase with gemcitabine and nab-paclitaxel failed to improve the median overall survival in patients with metastatic pancreatic cancer, missing the primary endpoint of the phase III HALO-301 trial, Halozyme Therapeutics, Inc. reported in a press release.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.